T1	intervention 32 44	Polyphenon E
T2	eligibility 499 568	women with stage I-III breast cancer who completed adjuvant treatment
T3	intervention-participants 607 609	16
T4	intervention-participants 624 626	11
T5	intervention-participants 644 645	3
T6	control 671 678	placebo
T7	control-participants 684 686	10
T8	duration 692 700	6Â months
T9	outcome-Measure 807 902	growth factor [serum hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF)]
T10	outcome-Measure 904 944	lipid (serum cholesterol, triglycerides)
T11	outcome-Measure 946 962	oxidative damage
T12	outcome-Measure 967 990	inflammatory biomarkers
T13	duration 992 1018	From July 2007-August 2009
T14	No-of-participants 1020 1022	40
T15	No-of-participants 1047 1049	34
T16	intervention-participants 1051 1053	26
T17	control-participants 1062 1067	eight
T18	outcome 1224 1245	mean serum HGF levels
T19	outcome 1385 1395	serum VEGF
T20	outcome 1563 1580	serum cholesterol
